261 related articles for article (PubMed ID: 31624127)
61. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
Tanaka H; Yoshida M; Tanimura H; Fujii T; Sakata K; Tachibana Y; Ohwada J; Ebiike H; Kuramoto S; Morita K; Yoshimura Y; Yamazaki T; Ishii N; Kondoh O; Aoki Y
Clin Cancer Res; 2011 May; 17(10):3272-81. PubMed ID: 21558396
[TBL] [Abstract][Full Text] [Related]
62. Frequency, impact and a preclinical study of novel
Elster N; Toomey S; Fan Y; Cremona M; Morgan C; Weiner Gorzel K; Bhreathnach U; Milewska M; Murphy M; Madden S; Naidoo J; Fay J; Kay E; Carr A; Kennedy S; Furney S; Mezynski J; Breathhnach O; Morris P; Grogan L; Hill A; Kennedy S; Crown J; Gallagher W; Hennessy B; Eustace A
Ther Adv Med Oncol; 2018; 10():1758835918778297. PubMed ID: 30023006
[TBL] [Abstract][Full Text] [Related]
63. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.
Vandekerkhove G; Todenhöfer T; Annala M; Struss WJ; Wong A; Beja K; Ritch E; Brahmbhatt S; Volik SV; Hennenlotter J; Nykter M; Chi KN; North S; Stenzl A; Collins CC; Eigl BJ; Black PC; Wyatt AW
Clin Cancer Res; 2017 Nov; 23(21):6487-6497. PubMed ID: 28760909
[No Abstract] [Full Text] [Related]
64. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
Gerratana L; Davis AA; Velimirovic M; Clifton K; Hensing WL; Shah AN; Dai CS; Reduzzi C; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Puglisi F; Ma CX; Bardia A; Cristofanilli M
Breast Cancer Res; 2023 Oct; 25(1):112. PubMed ID: 37784176
[TBL] [Abstract][Full Text] [Related]
65. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
[TBL] [Abstract][Full Text] [Related]
66. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
67. Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
Wang J; Chai YL; Wang T; Liu JH; Dai PG; Liu Z
Exp Mol Pathol; 2015 Jun; 98(3):407-10. PubMed ID: 25773678
[TBL] [Abstract][Full Text] [Related]
68. Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer.
Jiang W; Ouyang X; Li C; Long Y; Chen W; Ji Z; Shen X; Xiang L; Yang H
Immunology; 2023 Nov; 170(3):419-438. PubMed ID: 37469254
[TBL] [Abstract][Full Text] [Related]
69. Integrated mutational landscape analysis of uterine leiomyosarcomas.
Choi J; Manzano A; Dong W; Bellone S; Bonazzoli E; Zammataro L; Yao X; Deshpande A; Zaidi S; Guglielmi A; Gnutti B; Nagarkatti N; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Jeong K; Zhao S; Buza N; Hui P; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Ardighieri L; Bilguvar K; Quick CM; Silasi DA; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Imielinski M; Schwartz PE; Alexandrov LB; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876771
[TBL] [Abstract][Full Text] [Related]
70. Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
Krishnamurthy S; Yoda H; Hiraoka K; Inoue T; Lin J; Shinozaki Y; Watanabe T; Koshikawa N; Takatori A; Nagase H
Cancer Sci; 2021 Mar; 112(3):1141-1149. PubMed ID: 33377228
[TBL] [Abstract][Full Text] [Related]
71. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
72. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
[TBL] [Abstract][Full Text] [Related]
73. Cooperative oncogenic effect and cell signaling crosstalk of co‑occurring HER2 and mutant PIK3CA in mammary epithelial cells.
Dong L; Meng F; Wu L; Mitchell AV; Block CJ; Zhang B; Craig DB; Jang H; Chen W; Yang Q; Wu G
Int J Oncol; 2017 Oct; 51(4):1320-1330. PubMed ID: 28902361
[TBL] [Abstract][Full Text] [Related]
74. Targeting of β-Catenin Reverses Radioresistance of Cervical Cancer with the
Jiang W; Wu Y; He T; Zhu H; Ke G; Xiang L; Yang H
Mol Cancer Ther; 2020 Feb; 19(2):337-347. PubMed ID: 31666350
[TBL] [Abstract][Full Text] [Related]
75. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
76. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
77. Acquisition of Genetic Aberrations During the Progression of High-Grade Intraepithelial Lesions/Micro-Invasive Squamous Cancers to Widely Invasive Cervical Squamous Cell Cancer.
Kashofer K; Reich O; Regauer S
Arch Pathol Lab Med; 2023 Dec; 147(12):1438-1445. PubMed ID: 36800542
[TBL] [Abstract][Full Text] [Related]
78. High-Throughput Functional Evaluation of Variants of Unknown Significance in
Nagano M; Kohsaka S; Ueno T; Kojima S; Saka K; Iwase H; Kawazu M; Mano H
Clin Cancer Res; 2018 Oct; 24(20):5112-5122. PubMed ID: 29967253
[No Abstract] [Full Text] [Related]
79. Correlation between SNPs of PIK3CA, ERBB2 3'UTR, and their interactions with environmental factors and the risk of epithelial ovarian cancer.
Chen H; Zhai Z; Xie Q; Lai Y; Chen G
J Assist Reprod Genet; 2021 Oct; 38(10):2631-2639. PubMed ID: 33834328
[TBL] [Abstract][Full Text] [Related]
80. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Yadav G; Roque DM; Bellone S; Manavella DD; Hartwich TMP; Zipponi M; Harold J; Tymon-Rosario J; Mutlu L; Altwerger G; Menderes G; Ratner E; Buza N; Hui P; Huang GS; Andikyan V; Clark M; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Aug; 166(2):351-357. PubMed ID: 35641325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
